Search Orphan Drug Designations and Approvals
-
| Generic Name: | gabapentin enacarbil | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Name: | Horizant | ||||||||||||||||
| Date Designated: | 06/07/2011 | ||||||||||||||||
| Orphan Designation: | Treatment of postherpetic neuralgia | ||||||||||||||||
| Orphan Designation Status: | Designated/Approved | ||||||||||||||||
| Sponsor: |
Arbor Pharmaceuticals, LLC 6 Concourse Parkway Suite 1800 Atlanta, Georgia 30328 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
| 1 | Generic Name: | gabapentin enacarbil |
|---|---|---|
| Trade Name: | Horizant | |
| Marketing Approval Date: | 06/06/2012 | |
| Approved Labeled Indication: | Management of postherpetic neuralgia in adults. | |
| Exclusivity End Date: | 06/06/2019 | |
| Exclusivity Protected Indication* : | ||
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







